Last reviewed · How we verify
A Phase I, Maximum Tolerated Dose (MTD) Trial to Determine the Safety and Pharmacokinetics of Chronic Oral Administration of Farnesyl Transferase Inhibitor R115777 in Combination With Gemcitabine in Subjects With Advanced Incurable Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of combining R115777 with gemcitabine in treating patients with advanced cancer.
Details
| Lead sponsor | The University of Texas Health Science Center at San Antonio |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 22 |
| Start date | 1998-10 |
| Completion | 2002-11 |
Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
Interventions
- gemcitabine hydrochloride
- tipifarnib
Countries
United States